August 28th 2025
FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.
CEBF virtual symposium showcases vision research from three Northeast Ohio institutions
February 2nd 2022Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.
Read More
Studies: Faricimab improved and maintained vision for patients with wet AMD, DME
January 24th 2022Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.
Read More
Partnership develops video game software patented for age-related macular degeneration research
January 21st 2022A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options
Read More
Second pivotal trial in RGX-314 clinical program to begin
January 12th 2022ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.
Read More